TTS Pharma Limited, a London and Liverpool, UK-based company which is a vertically integrated supply chain manager in the cultivation, manufacturing and development of the emerging ethical cannabis market, closed a £10.3m Series B funding.
The company intends to use the funds to:
– expand its existing supply chain,
– develop its own facilities,
– strengthen its academic and commercial partnerships, and
– advance its diversified operations in the wellness, nutraceutical and pharmaceutical sectors.
In conjunction with the funding, TTS Pharma also announced the appointment of a new Executive Chairman, Paul Atherton.
Established in 2012 and led by CEO Mark Tucker, TTS Pharma develops products and holds deep industry expertise in extraction, separation and manufacturing of Cannabinoids.
The company, which has begun sales of its purified cannabis related products and technologies, abides by all legal and regulatory requirements in the UK and elsewhere and expects to gain further permissions related to these products in due course.